Stocks
Mutual Funds
ETFs
Pro Tools
Terminal
WealthView
Pricing
Learn More
stocksNATCOPHARM
resources
NATCOPHARM
967.85+1.5 (+0.16%)
9 Jul, 2:29 PM

Annual Reports and Financial Documents

Natco Pharma Ltd. annual reports, quarterly results, earnings call transcripts and investor presentations. All official filings in one place.

Corporate Announcements and Regulatory Filings

Natco Pharma Ltd. BSE/NSE disclosures, board meeting outcomes, insider trading notifications, acquisitions and other regulatory filings.
  • Outcome without intimation8 Jul 2026
    Board Meeting Outcome for Outcome Of Board Meeting
    Outcome of Board Meeting
  • Change in Management6 Jul 2026
    Announcement under Regulation 30 (LODR)-Change in Management
    Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
  • Change in Management30 Jun 2026
    Announcement under Regulation 30 (LODR)-Change in Management
    Superannuation of Mr. N. Malleswara Rao, Vice President - Operations, Pharma Division, Kothur w.e.f. closure of business hours on 30th June, 2026
  • Closure of Trading Window30 Jun 2026
    Closure of Trading Window
    Closure of Trading Window
  • Press Release / Media Release3 Jun 2026
    Announcement under Regulation 30 (LODR)-Press Release / Media Release
    NATCO Pharma Limited and Lupin Limited receive approval from U.S. FDA for Eribulin Mesylate Injection
  • Newspaper Publication30 May 2026
    Announcement under Regulation 30 (LODR)-Newspaper Publication
    Newspaper Publication of Annual Audited Financial Results for the Quarter and Year ended March 31, 2026
  • Analyst / Investor Meet30 May 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
    Audio Link of Concall held on May 29, 2026
  • Outcome of Board Meeting29 May 2026
    Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended 31St March, 2026
    Audited Financial Results for the quarter and year ended 31st March, 2026
  • Reg.24(A)-Annual Secretarial Compliance26 May 2026
    Compliances-Reg.24(A)-Annual Secretarial Compliance
    Annual Secretarial Compliance Report for FY 2025-26
  • Analyst / Investor Meet21 May 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
    Q4FY26 Audited Financial Results Earnings Call
  • Board Meeting18 May 2026
    Board Meeting Intimation for Considering Audited Financial Results For The Financial Year Ended 31St March, 2026
    Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve considering Audited Financial ....
  • General15 May 2026
    Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
    Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015
  • General14 May 2026
    Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
    Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
  • Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 20188 Apr 2026
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
    Compliance Certificates under Regulation 74(5) of SEBI (DP) Regulation, 2018
  • Closure of Trading Window31 Mar 2026
    Closure of Trading Window
    Trading Window closure for the quarter and year ending March 31, 2026
  • Postal Ballot25 Mar 2026
    Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
    E-voting Results of Postal Ballot Results
  • Acquisition24 Mar 2026
    Announcement under Regulation 30 (LODR)-Acquisition
    Outcome of the Board Meeting for incorporation of subsidiary Company in Nigeria
  • Scheme of Arrangement24 Mar 2026
    Announcement under Regulation 30 (LODR)-Scheme of Arrangement
    Outcome of Board Meeting
  • Outcome of Board Meeting24 Mar 2026
    Board Meeting Outcome for Outcome Of Board Meeting Held On 24Th March, 2026
    Outcome of the Board Meeting held on 24th March, 2026
  • Press Release / Media Release20 Mar 2026
    Announcement under Regulation 30 (LODR)-Press Release / Media Release
    NATCO Pharma Limited launches Semaglutide Generic Injection Multi Dose Vials in India at the Most Affordable Price starting from MRP INR 1290/-

Frequently Asked Questions

Where can I download the annual report of Natco Pharma Ltd.?
Annual reports of Natco Pharma Ltd. are available for download in the Annual Reports and Financial Documents section of the Resources tab, organised by financial year.
Where can I find the quarterly results of Natco Pharma Ltd.?
Quarterly earnings results and presentations of Natco Pharma Ltd. are available in the Annual Reports and Financial Documents section of the Resources tab. Detailed financials are also in the Statements tab.
Does Natco Pharma Ltd. publish earnings call transcripts?
Earnings call transcripts of Natco Pharma Ltd., where available, are listed in the Annual Reports and Financial Documents section of the Resources tab.
Where can I find investor presentations of Natco Pharma Ltd.?
Investor presentations and annual day presentations of Natco Pharma Ltd. are listed in the Resources tab under Annual Reports and Financial Documents.
What are the recent corporate announcements of Natco Pharma Ltd.?
Corporate announcements and regulatory filings of Natco Pharma Ltd. as submitted to BSE and NSE are available in the Corporate Announcements and Regulatory Filings section of the Resources tab.
How do I access the regulatory filings of Natco Pharma Ltd.?
Regulatory filings including board meeting outcomes, insider trading disclosures and other exchange notifications of Natco Pharma Ltd. are in the Corporate Announcements and Regulatory Filings section of the Resources tab.
What is the ISIN of Natco Pharma Ltd.?
The ISIN (International Securities Identification Number) of Natco Pharma Ltd. is INE987B01026. This is the unique identifier used across exchanges and depositories.
On which stock exchange is Natco Pharma Ltd. listed?
Natco Pharma Ltd. is listed on NSE and BSE. The NSE symbol is NATCOPHARM and the BSE code is -.
Where can I find the shareholding pattern of Natco Pharma Ltd.?
The quarterly shareholding pattern of Natco Pharma Ltd. showing promoter, FII, DII, mutual fund and public holdings is available in the Shareholding Pattern section on the Overview tab.
How current is the data for Natco Pharma Ltd. on Sharpely?
Share price data for Natco Pharma Ltd. is updated as of 9 Jul 2026. Financial statements, shareholding and other fundamental data are updated after each quarterly disclosure.